ATE493437T1 - Polypeptide für die oligomerisierung von antigenen - Google Patents

Polypeptide für die oligomerisierung von antigenen

Info

Publication number
ATE493437T1
ATE493437T1 AT05770330T AT05770330T ATE493437T1 AT E493437 T1 ATE493437 T1 AT E493437T1 AT 05770330 T AT05770330 T AT 05770330T AT 05770330 T AT05770330 T AT 05770330T AT E493437 T1 ATE493437 T1 AT E493437T1
Authority
AT
Austria
Prior art keywords
polypeptides
polypeptide
oligomerisation
oligomerization
antigens
Prior art date
Application number
AT05770330T
Other languages
English (en)
Inventor
Barbara Capecchi
Vega Masignani
Rino Rappuoli
Maria Scarselli
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE493437T1 publication Critical patent/ATE493437T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT05770330T 2004-07-23 2005-07-22 Polypeptide für die oligomerisierung von antigenen ATE493437T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59064804P 2004-07-23 2004-07-23
PCT/IB2005/002528 WO2006011060A2 (en) 2004-07-23 2005-07-22 Polypeptides for oligomeric assembly of antigens

Publications (1)

Publication Number Publication Date
ATE493437T1 true ATE493437T1 (de) 2011-01-15

Family

ID=35447945

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05770330T ATE493437T1 (de) 2004-07-23 2005-07-22 Polypeptide für die oligomerisierung von antigenen

Country Status (8)

Country Link
US (1) US7915218B2 (de)
EP (1) EP1778725B1 (de)
CN (1) CN101014618B (de)
AT (1) ATE493437T1 (de)
CA (1) CA2574375C (de)
DE (1) DE602005025647D1 (de)
ES (1) ES2355980T3 (de)
WO (1) WO2006011060A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9808932D0 (en) * 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
JP2008528512A (ja) 2005-01-21 2008-07-31 エピトピックス，リミティド ライアビリティ カンパニー エルシニアｓｐｐ．ポリペプチド及び使用方法
EP1945250A4 (de) * 2005-08-16 2010-05-19 Hawaii Biotech Inc Rekombinante subunit-vakzine gegen influenza
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
EP1972350A1 (de) * 2007-03-20 2008-09-24 Rijksuniversiteit Groningen Duales Targeting-System
EA200700940A1 (ru) * 2007-04-27 2007-12-28 Петр Генриевич ЛОХОВ Способ получения противоопухолевой вакцины на основе поверхностных антигенов эндотелиальных клеток
EP2003144A1 (de) * 2007-06-15 2008-12-17 Institut Pasteur Diagnose- oder Screening-Verfahren für eine Arbovirusinfektion, Reagenzien für dieses Verfahren und deren Anwendung
GB0711858D0 (en) * 2007-06-19 2007-07-25 Glaxosmithkline Biolog Sa Vaccine
US8642046B2 (en) * 2007-10-09 2014-02-04 Tufts University Cholera vaccines
JP5261775B2 (ja) * 2008-02-22 2013-08-14 国立大学法人名古屋大学 微生物に対して非特異的付着性及び／又は凝集性を付与又は増強する方法及び遺伝子
ES2918381T3 (es) 2009-07-15 2022-07-15 Glaxosmithkline Biologicals Sa Composiciones de proteína F de VRS y métodos para producir las mismas
EP3831406B1 (de) 2010-08-23 2024-06-05 Wyeth LLC Stabile formulierungen von neisseria-meningitidis-rlp2086-antigenen
AU2011300409B2 (en) 2010-09-10 2015-03-26 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
PT2707385T (pt) 2011-05-13 2017-12-19 Glaxosmithkline Biologicals Sa Antigénios de f de rsv pré-fusão
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MX351993B (es) 2012-03-09 2017-11-03 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
US20150050311A1 (en) * 2012-04-05 2015-02-19 Ludwig-Maximilians-Universitat München Novel method for the preparation of a strain-adapted vaccine
WO2014018858A2 (en) * 2012-07-26 2014-01-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Multimeric fusion protein vaccine and immunotherapeutic
US10000545B2 (en) 2012-07-27 2018-06-19 Institut National De La Sante Et De La Recherche Medicale CD147 as receptor for pilus-mediated adhesion of Meningococci to vascular endothelia
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
MX369534B (es) 2013-09-08 2019-11-11 Pfizer Composiciones de neisseria meningitidis y sus metodos.
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
RU2723045C2 (ru) 2015-02-19 2020-06-08 Пфайзер Инк. Композиции neisseria meningitidis и способы их получения
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
JP7010961B2 (ja) 2017-01-31 2022-02-10 ファイザー・インク 髄膜炎菌組成物およびその方法
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
WO2021188818A1 (en) * 2020-03-19 2021-09-23 The United States Of America As Represented By The Secretary Of The Navy Vaccine constructs and compositions and methods of use thereof
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9106048D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccines
US5837544A (en) 1995-02-02 1998-11-17 Cell Genesys, Inc. Method of inducing a cell to proliferate using a chimeric receptor comprising janus kinase
US6716429B1 (en) * 1997-10-01 2004-04-06 Dana-Farber Cancer Institute, Inc. Stabilization of envelope glycoprotein trimers by disulfide bonds introduced into a gp 41 glycoprotein ectodomain
US20040053249A1 (en) 2000-05-26 2004-03-18 Junko Tohma Fas ligand-fused proteins

Also Published As

Publication number Publication date
WO2006011060A2 (en) 2006-02-02
EP1778725B1 (de) 2010-12-29
CA2574375C (en) 2015-03-17
CN101014618B (zh) 2013-01-02
EP1778725A2 (de) 2007-05-02
US20080260769A1 (en) 2008-10-23
CN101014618A (zh) 2007-08-08
DE602005025647D1 (de) 2011-02-10
US7915218B2 (en) 2011-03-29
ES2355980T3 (es) 2011-04-01
WO2006011060A3 (en) 2006-04-06
CA2574375A1 (en) 2006-02-02

Similar Documents

Publication Publication Date Title
ATE493437T1 (de) Polypeptide für die oligomerisierung von antigenen
MX2014005546A (es) Anticuerpos de union de albumina y fragmentos de union de los mismos.
CL2018001827A1 (es) Proteína de unión de tipo anticuerpo con región variable dual que comprende cuatro cadenas polipeptídicas que forman cuatro sitios de unión a antígeno; molécula de ácido nucleico que la codifica; vector de expresión; célula; método de elaboración; y composición farmacéutica que la comprende (divisional solicitud 201302763)
WO2019068018A3 (en) Recombinant collagen and elastin molecules and uses thereof
MY148646A (en) Anti-psgl-1 antibodies
CO2018005436A2 (es) Anticuerpos y fragmentos de anticuerpo para la conjugación sitio-específica
PH12019500782A1 (en) Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
ATE433491T1 (de) Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential
MX2012009175A (es) Metodos para identificar y aislar celulas que expresan un polipeptido.
PE20150023A1 (es) Proteinas de union a antigeno st2
SG10201806693XA (en) Anti-myostatin antibodies and methods of use
WO2013155526A3 (en) Sortase- modified vhh domains and uses thereof
NZ591704A (en) Peptide vaccines for cancers expressing tumor-associated antigens
BRPI0508551A (pt) seqüências de ácidos nucléicos de lactobacillus acidophilus que codificam proteìnas relacionadas à utilização de carboidrato e usos dessas
CL2010001427A1 (es) Proteina de union que comprende una cadena polipeptidica capaz de unir un par de antigenos; acido nucleico aislado que codifica dicha proteina de union; vector y celula huesped; metodo para producir proteina de union; composicion farmaceutica que comprende dicha proteina.
WO2019195314A3 (en) Antigenic epstein barr virus polypeptides
MX2021000030A (es) Metodos y composiciones que utilizan polipeptidos variantes klotho.
WO2019195623A3 (en) Heterodimeric antibodies that bind fibroblast activation protein
MX2016008355A (es) Anticuerpos que comprenden extensiones de polipeptidos de cadena ligera en el extremo c y conjugados y metodos de uso de estos.
AR085167A1 (es) Polipeptidos de porphyromonas gingivalis, metodo de tratamiento, uso, anticuerpo y kit
MX2021000155A (es) Moleculas de proteina multifuncionales que comprenden decorina y su uso.
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
AR095199A1 (es) Anticuerpos anti-cd52
MX2021001129A (es) Metodo de purificacion de antigenos.
WO2021239838A3 (en) Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties